Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The present study is a randomized, control, phase II/III study of early stage (FIGO Ia2-IIb)
cervical cancer after radical hysterectomy in Northwest China treated with radiotherapy or
concurrent chemoradiotherapy based on the surgical-pathological risk factors. All the
patients received whole pelvis radiation and were divided into three groups according to
adjuvant chemotherapy: concurrent chemotherapy with cisplatin weekly (40mg/m2) , concurrent
chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), or concurrent and adjuvant
chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2). The effectiveness, and side
effects will be evaluated according to Standard WHO response criteria, and NCI common
toxicity criteria for adverse events(NCI-CTC-AE) V3.0.